Table 2 Patient characteristics at baseline stratified by mPEW-S

 Age, years

62 ± 12

57 ± 12

63 ± 11

71 ± 12

< 0.001

 Male sex, n (%)

85 (59)

41 (68)

32 (51)

12 (57)

0.147

 Diabetic nephropathy, n (%)

17 (11.9)

7 (12)

6 (10)

4 (19)

0.554

 History of cardiovascular diseases, n (%)

20 (14)

4 (7)

12 (19)

4 (19)

0.062

 Dialysis history, years

11 (5-22)

14 (8-27)

7 (3-19)

8 (7-14)

0.228

 Kt/V for urea

1.71 ± 0.31

1.68 ± 0.33

1.75 ± 0.27

1.66 ± 0.34

0.858

 Normalized protein catabolic rate, g/kg/day

0.93 ± 0.17

0.96 ± 0.15

0.95 ± 0.15

0.78 ± 0.18

< 0.001

 Dry weight, kg

57.0 ± 10.9

59.7 ± 10.5

56.8 ± 10.4

49.8 ± 10.7

< 0.001

 Body mass index, kg/m²

22.2 ± 3.5

22.7 ± 3.6

22.5 ± 3,1

19.8 ± 3.7

0.006

 Hemoglobin, g/dL

11.2 ± 1.1

11.4 ± 0.9

11.0 ± 1.3

10.9 ± 1.0

0.023

 Albumin, g/dL

3.7 ± 0.3

4.0 ± 0.1

3.6 ± 0.3

3.4 ± 0.2

< 0.001

 C-reactive protein, mg/dL

0.1 (0.1-0.3)

0.1 (0.1-0.2)

0.2 (0.1-0.4)

0.4 (0.1-1.9)

0.004

 Urea nitrogen, mg/dL

64 ± 14

67 ± 12

65 ± 13

51 ± 15

< 0.001

 Creatinine, mg/dL

10.7 ± 2.5

11.8 ± 2.2

10.7 ± 2.3

7.8 ± 1.6

< 0.001

 Calcium, mg/dL

9.4 ± 0.5

9.6 ± 0.5

9.2 ± 0.5

9.1 ± 1.0

< 0.001

 Phosphate, mg/dL

4.6 ± 0.9

4.8 ± 0.8

4.5 ± 0.9

4.6 ± 1.0

0.114

 PTH (intact assay), pg/mL

72 (41–117)

82 (45–123)

62 (36–112)

76 (49–90)

0.161

 Anti-hypertensive drugs, n (%)

90 (54)

38 (63)

40 (63)

12 (57)

0.689

 ESAs, n (%)

122 (85)

50 (83)

54 (86)

18 (86)

0.730

 VDRAs, n (%)

106 (74)

44 (73)

47 (75)

15 (71)

0.937

 Phosphate binders, n (%)

115 (80)

48 (80)

52 (83)

15 (71)

0.970

 Cinacalcet hydrochloride, n (%)

36 (25)

14 (23)

14 (22)

8 (38)

0.322